Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Lilly is a large, diversified global pharmaceutical company with a core high-revenue portfolio.
|
$985.74B |
$1063.02
+2.07%
|
|
JNJ
Johnson & Johnson
Johnson & Johnson's portfolio includes multiple monoclonal antibody therapeutics (e.g., DARZALEX, CARVYKTI, TECVAYLI, TALVEY) across oncology and immunology.
|
$492.05B |
$205.33
+0.50%
|
|
ABBV
AbbVie Inc.
AbbVie directly commercializes monoclonal antibody therapeutics (e.g., Skyrizi) as a core immunology asset.
|
$388.96B |
$223.91
+1.69%
|
|
AZN
AstraZeneca PLC
AZN is a large-cap pharmaceutical company with a diversified, global drug portfolio and a robust R&D pipeline.
|
$282.78B |
$94.78
+3.90%
|
|
MRK
Merck & Co., Inc.
The company markets vaccines (Capvaxive) and has historical Gardasil sales, making vaccines a core product category.
|
$268.36B |
$109.05
+1.49%
|
|
NVO
Novo Nordisk A/S
Novo Nordisk is a leading large-cap pharmaceutical company with blockbuster GLP-1 products Wegovy and Ozempic, a core driver of its revenue and growth.
|
$248.55B |
$56.16
+1.91%
|
|
TMO
Thermo Fisher Scientific Inc.
Thermo Fisher provides companion diagnostics (e.g., Oncomine Dx tests) that inform targeted therapies.
|
$230.80B |
$621.97
+1.76%
|
|
ABT
Abbott Laboratories
Abbott competes in generic drug segments across emerging markets, aligning with the Generic Drugs theme within Established Pharmaceutical Products.
|
$220.08B |
$128.22
+1.40%
|
|
AMGN
Amgen Inc.
Amgen's portfolio includes monoclonal antibody therapeutics such as Repatha and tezepelumab (TEZSPIRE).
|
$172.66B |
$329.68
+2.79%
|
|
GILD
Gilead Sciences, Inc.
Trodelvy is a TROP2-targeted antibody-drug conjugate (ADC), a core oncology modality.
|
$146.79B |
$121.58
+2.77%
|
|
PFE
Pfizer Inc.
Pfizer's vaccines portfolio (e.g., Comirnaty and other RSV vaccines) is a core, revenue-driving product line.
|
$143.11B |
$25.51
+1.35%
|
|
VRTX
Vertex Pharmaceuticals Incorporated
Vertex is a large-cap pharma/biotech with a diversified, revenue-generating portfolio anchored by CFTR modulators and expanding pipeline.
|
$115.07B |
$466.52
+3.95%
|
|
BMY
Bristol-Myers Squibb Company
Immunology Therapeutics captures BMY's immune-mediated disease focus beyond oncology.
|
$108.00B |
$54.65
+2.99%
|
Showing page 1 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
